With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Max Gelman

Senior Editor

Insilico Medicine reported Phase 2a results for its lead program, saying the study achieved its primary endpoint of safety and tolerability. But the efficacy data …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Max Gelman

Senior Editor

Sign up to read this article for free.

Stem cell startup spun out of George Church’s lab raises $75M

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Upstream Bio files for IPO in sign of life for biotech public offerings

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

Breaking down silos with a new quantitative approach to drug development

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

Max Gelman

Senior Editor

Sign up to read this article for free.

Stem cell start­up spun out of George Church’s lab rais­es $75M

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Stem cell startup spun out of George Church’s lab raises $75M

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Upstream Bio files for IPO in sign of life for biotech public offerings

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

Breaking down silos with a new quantitative approach to drug development